Drugs / ODM-109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02487407 | Jul 2015 → May 2017 | amyotrophic lateral sclerosis | Orion Corporation, Orion Pharma | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ODM-109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02487407 ↗ |
| Route | Oral | “ODM-109 capsules for oral administration” NCT02487407 ↗ |